Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.65 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.49 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 11/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17840412 | 1.00 | TLR8 (0.65) | TLR8TLR9TLR7PBKAR | |
| SCHEMBL19957396 | 0.87 | TLR8 (0.53) | TLR8TLR9TLR7AR | |
| SCHEMBL4876295 | 0.85 | AR (0.63) | TLR8TLR9TLR7AR | |
| SCHEMBL30003477 | 0.83 | PBK (0.50) | TLR8PBK | |
| SCHEMBL21795290 | 0.82 | TLR8 (0.54) | TLR8TLR9TLR7AR | |
| SCHEMBL21795382 | 0.82 | TLR8 (0.54) | TLR8TLR9TLR7AR | |
| SCHEMBL16661650 | 0.81 | TLR8 (0.72) | TLR8TLR9TLR7 | |
| SCHEMBL16653616 | 0.81 | TLR8 (0.72) | TLR8TLR9TLR7 | |
| SCHEMBL19000101 | 0.81 | TLR8 (0.78) | TLR8TLR9TLR7ARDPP4 | |
| SCHEMBL26351021 | 0.81 | TLR8 (0.62) | TLR8TLR9TLR7AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057948-B1 | SELECTIVELY SUBSTITUTED QUINOLINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-03-14 | — | — | EP | claimed |
| US-9663486-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-05-30 | — | — | US | claimed |
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-06-23 | — | — | US | claimed |
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | TLR8 3/4885TLR9 4/4885TLR7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.